Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.61 |
| ▸ | CNR2 | P34972 | 3/20 | 0.57 |
| ▸ | CNR1 | P21554 | 2/20 | 0.57 |
| ▸ | KIT | P10721 | 4/20 | 0.55 |
| ▸ | BTK | Q06187 | 2/20 | 0.49 |
| ▸ | STK4 | Q13043 | 3/20 | 0.48 |
| ▸ | STK3 | Q13188 | 3/20 | 0.48 |
| ▸ | AKT1 | P31749 | 2/20 | 0.47 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.47 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30295133 | 0.89 | LRRK2 (0.61) | LRRK2CNR2CNR1KITBTK | |
| SCHEMBL29247128 | 0.89 | LRRK2 (0.61) | LRRK2CNR2CNR1KITBTK | |
| SCHEMBL30295134 | 0.89 | LRRK2 (0.61) | LRRK2CNR2CNR1KITBTK | |
| SCHEMBL28367334 | 0.87 | AKT1 (0.55) | CNR2CNR1KITBTKAKT1 | |
| SCHEMBL29247486 | 0.85 | KIT (0.55) | LRRK2CNR2CNR1KITBTK | |
| SCHEMBL30372597 | 0.85 | KIT (0.55) | LRRK2CNR2CNR1KITBTK | |
| SCHEMBL28129919 | 0.85 | LRRK2 (0.61) | LRRK2CNR2KITSTK4STK3 | |
| SCHEMBL16636776 | 0.82 | LRRK2 (0.66) | LRRK2CNR2KITSTK4STK3 | |
| SCHEMBL28367843 | 0.81 | AKT1 (0.57) | KITBTKAKT1AKT1S1 | |
| SCHEMBL2253309 | 0.81 | AKT1 (0.57) | KITBTKAKT1AKT1S1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-02-08 | — | — | US | disclosed |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2024-01-23 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20220242875-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2022-08-04 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| WO-2016044772-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| WO-2016044772-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC (US) | 2016-03-24 | — | — | WO | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | LRRK2 53/4885CNR2 4274/4885CNR1 3613/4885 |
| US-11878985-B2 | Substituted quinazolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | LRRK2 63/4885CNR2 3665/4885CNR1 2883/4885 |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | LRRK2 63/4885CNR2 3665/4885CNR1 2883/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | LRRK2 40/4885CNR2 4236/4885CNR1 3222/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | LRRK2 40/4885CNR2 4236/4885CNR1 3222/4885 |
| US-20240043441-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | LRRK2 40/4885CNR2 4236/4885CNR1 3222/4885 |
| US-20230303586-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | LRRK2 40/4885CNR2 4236/4885CNR1 3222/4885 |
| US-20220242875-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | LRRK2 40/4885CNR2 4236/4885CNR1 3222/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | LRRK2 2016/4885CNR2 4414/4885CNR1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.